ALIOF
Actelion Ltd.  |  OTCPK - Current
52wk high:233.84
52wk low:125.16
EPS:6.60
PE (ttm):34.29
Div Rate (ttm):1.50
Yield (ttm):0.66%
Market Cap:$22.38B
Volume:
  • Fri, Jan. 6, 3:23 AM
    • Complicated takeover? Johnson & Johnson (NYSE:JNJ) and Actelion (OTCPK:ALIOY) have asked Switzerland's takeover board about a deal structure that would separate the latter's commercialized portfolio from its R&D assets, Tages-Anzeiger reports.
    • That would allow J&J to acquire Actelion with a cash offer in the region of $260 per share, a little more than what it had offered when it walked away from negotiations in December.
    Fri, Jan. 6, 3:23 AM | 6 Comments
  • Dec. 29, 2016, 11:07 AM
    • Johnson & Johnson (JNJ +0.3%) is talking about breaking up Actelion (OTCPK:ALIOY) in an acquisition deal, Reuters reports.
    • JNJ had edged out Sanofi from the bidding after entering exclusive talks with the Swiss biotech. Now the negotiations involve separating Actelion's commercialized portfolio from research and development.
    • That would provide for an acquisition in the range of $260/share (slightly more than a previously rejected $250/share) and yet allow Actelion holders to benefit from the R&D pipeline, which would be put into a new publicly traded company.
    Dec. 29, 2016, 11:07 AM | 28 Comments
  • Dec. 22, 2016, 3:42 AM
    • Johnson & Johnson (NYSE:JNJ) has re-entered the race to acquire Actelion (OTCPK:ALIOY) and is now in exclusive talks with the Swiss biotech firm, sidelining Sanofi (NYSE:SNY) from the bidding process.
    • However, Actelion - which has fended off takeover attempts in the past - cautioned that there could be "no assurances" that its talks with J&J would result in a deal.
    • Actelion shares +7.5% in Zurich.
    Dec. 22, 2016, 3:42 AM | 4 Comments
  • Dec. 21, 2016, 3:59 AM
    • Takeover talks between Actelion (OTCPK:ALIOY) and Sanofi (NYSE:SNY) are making progress, despite concerns the boss of the Swiss biotech firm may be against the idea of selling.
    • According to Reuters, Actelion has reached a point where it can't call off negotiations without triggering an investor rebellion demanding the overthrow of its board.
    • Shares in Actelion are up 3.6% in Zurich.
    Dec. 21, 2016, 3:59 AM | 5 Comments
  • Dec. 16, 2016, 3:38 AM
    • Sanofi (NYSE:SNY), long suspected of coveting Swiss drugmaker Actelion (OTCPK:ALIOF), is in advanced talks to buy the company and is discussing a takeover price of ~$275/share, Bloomberg reports.
    • The price may include a contingent value right for Actelion shareholders, which would pay out depending on the future performance of certain pipeline drugs, according to the report.
    • The potential deal, which would value Actelion at ~$29.6B and follows Johnson & Johnson's reported withdrawal from the bidding, could come as soon as next week.
    Dec. 16, 2016, 3:38 AM | 8 Comments
  • Dec. 13, 2016, 6:50 PM
    • Johnson & Johnson (NYSE:JNJ) has reportedly ended its negotiations with Actelion Pharmaceuticals (OTCPK:ALIOF) about a possible merger. J&J had made a $20B ($250/share) for the Basel, Switzerland-based biopharma firm, up from its original offer of $17B after Actelion resisted.
    • Sanofi (NYSE:SNY) is reportedly mulling a bid as well.
    • Update: In a statement, J&J says its was unable to reach an agreement that it believed would "create adequate value" for its shareholders.
    Dec. 13, 2016, 6:50 PM | 25 Comments
  • Nov. 29, 2016, 2:50 AM
    • Actelion (OTCPK:ALIOY) is considering a complicated deal to combine with part of Johnson & Johnson (NYSE:JNJ), a move that will leave the Swiss company independent from the U.S. drugs giant, FT reports.
    • The structured transaction would create a new, larger biotech firm uniting Actelion with relevant parts of J&J's pharma business, with the latter becoming a major shareholder in the new business.
    Nov. 29, 2016, 2:50 AM | 2 Comments
  • Nov. 25, 2016, 1:52 AM
    • Johnson & Johnson (NYSE:JNJ) has approached Actelion (OTCPK:ALIOY) about a potential takeover in a bid to boost its pharma business, Bloomberg reports.
    • Europe's largest biotech firm has two pulmonary arterial hyper tension drugs which J&J would love to get its hands on, but deliberations are still at an early stage.
    • Shares in Actelion are up around 13% so far this year, valuing the company at around $17B.
    Nov. 25, 2016, 1:52 AM | 6 Comments
  • Oct. 20, 2016, 9:18 AM
    Oct. 20, 2016, 9:18 AM
  • Jul. 21, 2016, 8:31 AM
    • Actelion (OTCPK:ALIOF): 1H16 EPS of CHF4.05
    • Revenue of CHF1.18B (+16.8% Y/Y)
    Jul. 21, 2016, 8:31 AM
  • Apr. 21, 2016, 8:48 AM
    • Actelion (OTCPK:ALIOF): Q1 EPS of CHF1.98.
    • Revenue of CHF590M (+14.6% Y/Y).
    Apr. 21, 2016, 8:48 AM
  • Feb. 9, 2016, 8:46 AM
    • Actelion (OTCPK:ALIOF): Q4 EPS of CHF0.91
    • Revenue of CHF519.76M (+11.0% Y/Y)
    Feb. 9, 2016, 8:46 AM
  • Dec. 22, 2015, 10:12 AM
    • The FDA approves Actelion Pharmaceuticals' (OTCPK:ALIOF)(OTCPK:ALIOY) Orphan Drug-tagged selexipag tablets, branded as Uptravi, for the treatment of adults with pulmonary arterial hypertension (PAH), high blood pressure that occurs in arteries that connect the heart to the lungs.
    • Uptravi is eligible for a seven-year period of market exclusivity for the indication as afforded under Orphan Drug status.
    • The company submitted its Marketing Authorization Application (MAA) in Europe a year ago.
    • Selexipag, licensed from Nippon Shinyaku, is a selective prostacyclin receptor (IP receptor) agonist. Prostacyclin activates the IP receptor which induces the dilation of the blood vessels while inhibiting the proliferation of vascular smooth muscle cells.
    • Previously: Actelion submits MAA for pulmonary hypertension drug (Dec. 3, 2014)
    Dec. 22, 2015, 10:12 AM
  • Sep. 10, 2015, 5:28 PM
    • With ZS Pharma (NASDAQ:ZSPH) surging 28% today as investors bought in with takeover on their minds, Actelion Pharmaceuticals (OTCPK:ALIOY +2.5%) has confirmed it's started preliminary talks with ZS.
    • ZS Pharma shares were up this morning, surged again after 2:20 p.m. today and were halted for news after the close.
    • Earlier, the company canceled its presentation and one-on-ones at a Citi investor conference, stoking memories of Kythera's similar cancellation prior to an acquisition several months ago.
    • More than 6.7M shares traded hands today against a daily average of about 439K.
    • Updated with ZS Pharma's 5:31 p.m. statement: "ZS Pharma today confirmed that it has participated in preliminary discussions with Actelion Ltd. regarding a potential strategic transaction. ZS Pharma regularly and routinely explores opportunities with various strategic partners and will continue to do so. These discussions may or may not lead to any transaction."
    Sep. 10, 2015, 5:28 PM | 2 Comments
  • Jun. 7, 2015, 4:55 PM
    Jun. 7, 2015, 4:55 PM
  • Mar. 26, 2015, 8:08 AM
    • The Japanese Ministry of Health, Labour and Welfare approves Actelion's (OTCPK:ALIOF) (OTCPK:ALIOY) Opsumit (macitentan) for the treatment of pulmonary arterial hypertension (PAH). The approval was based on the results in the SERAPHIN Phase 3 trial that showed patients treated with macitentan 10 mg per day experienced a 45% risk reduction (p<0.0001) of the composite morbidity-mortality endpoint compared to placebo.
    • The company will co-promote Opsumit in Japan with Nippon Shinyaku.
    • Opsumit was cleared by the FDA in October 2013 and by the European Commission (EC) in December 2013.
    Mar. 26, 2015, 8:08 AM